The Food and Drug Administration approved Moderna’s new lower-dose COVID-19 vaccine over the weekend.

The FDA stressed that this is not considered a replacement for the company’s existing shot but can be considered as a second option.

mNexspike

Dig deeper:

Moderna’s new COVID-19 vaccine, named mNexspike, is a fifth of the dose of its current COVID-19 vaccine, Spikevax.

It is considered a step toward next-generation coronavirus vaccines.

mNexspike is approved for use in all adults 65 and older and for people aged 12 to 64 with at least one health condition that puts them at increased risk from COVID-19.

Why you should care:

Moderna’s existing vaccine doesn’t face those limits and has long been used for anyone ages 6 months and older.

What's next:

The company said it expected to

See Full Page